1 |
Fanelli V, Ranieri VM. Mechanisms and clinical consequences of acute lung injury[J]. Ann Am Thorac Soc, 2015, 12: S3-S8.
|
2 |
Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries[J]. JAMA, 2016, 315(8): 788-800.
|
3 |
Yang XB, Yu Y, Xu JQ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5): 475-481.
|
4 |
Curley GF, Laffey JG, Zhang HB, et al. Biotrauma and ventilator-induced lung injury: clinical implications[J]. Chest, 2016, 150(5): 1109-1117.
|
5 |
Albert RK, Smith B, Perlman CE, et al. Is progression of pulmonary fibrosis due to ventilation-induced lung injury?[J]. Am J Respir Crit Care Med, 2019, 200(2): 140-151.
|
6 |
Combes A, Pesenti A, Ranieri VM. Fifty years of research in ARDS.Is extracorporeal circulation the future of acute respiratory distress syndrome management?[J]. Am J Respir Crit Care Med, 2017, 195(9): 1161-1170.
|
7 |
Shaw TD, McAuley DF, O'Kane CM. Emerging drugs for treating the acute respiratory distress syndrome[J]. Expert Opin Emerg Drugs, 2019, 24(1): 29-41.
|
8 |
Liu A, Zhang XW, He H, et al. Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease[J]. Expert Opin Biol Ther, 2020, 20(2): 125-140.
|
9 |
Han JB, Li YM, Li YY. Strategies to enhance mesenchymal stem cell-based therapies for acute respiratory distress syndrome[J]. Stem Cells Int, 2019, 2019: 5432134.
|
10 |
Li JW, Wu X. Mesenchymal stem cells ameliorate LPS-induced acute lung injury through KGF promoting alveolar fluid clearance of alveolar type II cells[J]. Eur Rev Med Pharmacol Sci, 2015, 19(13): 2368-2378.
|
11 |
Hu SL, Li JZ, Xu XP, et al. The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo[J]. Stem Cell Res Ther, 2016, 7(1): 1-13.
|
12 |
Yang Y, Chen QH, Liu AR, et al. Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway[J]. Stem Cell Res Ther, 2015, 6(1): 1-14.
|
13 |
Lu ZH, Chang W, Meng SS, et al. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury[J]. Stem Cell Res Ther, 2019, 10(1): 372.
|
14 |
Xu N, Shao Y, Ye KL, et al. Mesenchymal stem cell-derived exosomes attenuate phosgene-induced acute lung injury in rats[J]. Inhal Toxicol, 2019, 31(2): 52-60.
|
15 |
Tang XD, Shi L, Monsel A, et al. Mesenchymal stem cell microvesicles attenuate acute lung injury in mice partly mediated by Ang-1 mRNA[J]. Stem Cells Dayt Ohio, 2017, 35(7): 1849-1859.
|
16 |
Cai SX, Liu AR, Chen S, et al. Activation of Wnt/β-catenin signalling promotes mesenchymal stem cells to repair injured alveolar epithelium induced by lipopolysaccharide in mice[J]. Stem Cell Res Ther, 2015, 6: 65.
|
17 |
Gupta N, Su X, Popov BV, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice[J]. J Immunol, 2007, 179(3): 1855-1863.
|
18 |
Mao YX, Xu JF, Seeley EJ, et al. Adipose tissue-derived mesenchymal stem cells attenuate pulmonary infection caused by Pseudomonas aeruginosavia inhibiting overproduction of prostaglandin E2[J]. Stem Cells Dayt Ohio, 2015, 33(7): 2331-2342.
|
19 |
Zhu H, Xiong Y, Xia YQ, et al. Therapeutic effects of human umbilical cord-derived mesenchymal stem cells in acute lung injury mice[J]. Sci Rep, 2017, 7: 39889.
|
20 |
Ji SM, Wu CM, Tong L, et al. Better therapeutic potential of bone marrow-derived mesenchymal stem cells compared with chorionic villi-derived mesenchymal stem cells in airway injury model[J]. Regen Med, 2019, 14(3): 165-177.
|
21 |
Wang LL, Shi M, Tong L, et al. Lung-resident mesenchymal stem cells promote repair of LPS-induced acute lung injury via regulating the balance of regulatory T cells and Th17 cells[J]. Inflammation, 2019, 42(1): 199-210.
|
22 |
Horie S, Masterson C, Devaney J, et al. Stem cell therapy for acute respiratory distress syndrome: a promising future?[J]. Curr Opin Crit Care, 2016, 22(1): 14-20.
|
23 |
Kumar PA, Hu Y, Yamamoto Y, et al. Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection[J]. Cell, 2011, 147(3): 525-538.
|
24 |
Zuo W, Zhang T, Wu DZ, et al. p63+Krt5+ distal airway stem cells are essential for lung regeneration[J]. Nature, 2015, 517(7536): 616-620.
|
25 |
Wilson JG, Liu KD, Zhuo HJ, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial[J]. Lancet Respir Med, 2015, 3(1): 24-32.
|
26 |
刘薇薇, 余卫, 陈嘉榆, 等. 脐带间充质干细胞治疗急性百草枯中毒致肺损伤临床观察[J]. 中华劳动卫生职业病杂志, 2012, 30(11): 811-815.
|
27 |
Matthay MA, Calfee CS, Zhuo HJ, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial[J]. Lancet Respir Med, 2019, 7(2): 154-162.
|
28 |
Islam D, Huang YB, Fanelli V, et al. Identification and modulation of microenvironment is crucial for effective mesenchymal stromal cell therapy in acute lung injury[J]. Am J Respir Crit Care Med, 2019, 199(10): 1214-1224.
|
29 |
Xu XP, Huang LL, Hu SL, et al. Genetic modification of mesenchymal stem cells overexpressing angiotensin II type 2 receptor increases cell migration to injured lung in LPS-induced acute lung injury mice[J]. Stem Cells Transl Med, 2018, 7(10): 721-730.
|
30 |
Yang JX, Zhang N, Wang HW, et al. CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats[J]. J Biol Chem, 2015, 290(4): 1994-2006.
|
31 |
Han JB, Lu XM, Zou LJ, et al. E-prostanoid 2 receptor overexpression promotes mesenchymal stem cell attenuated lung injury[J]. Hum Gene Ther, 2016, 27(8): 621-630.
|
32 |
Min F, Gao FY, Li Q, et al. Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury[J]. Mol Med Rep, 2015, 11(4): 2387-2396.
|
33 |
Zhang SQ, Jiang W, Ma LJ, et al. Nrf2 transfection enhances the efficacy of human amniotic mesenchymal stem cells to repair lung injury induced by lipopolysaccharide[J]. J Cell Biochem, 2018, 119(2): 1627-1636.
|
34 |
Zhou YQ, Shi Y, Yang L, et al. Genetically engineered distal airway stem cell transplantation protects mice from pulmonary infection[J]. EMBO Mol Med, 2020, 12(1): e10233.
|
35 |
Bułdak Ł, Machnik G, Bułdak RJ, et al. Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner[J]. Pharmacol Rep, 2016, 68(2): 329-337.
|
36 |
Feng Y, Wang LL, Ma XY, et al. Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway[J]. Stem Cell Res Ther, 2020, 11(1): 2.
|
37 |
Zhang ZL, Li WF, Heng ZZ, et al. Combination therapy of human umbilical cord mesenchymal stem cells and FTY720 attenuates acute lung injury induced by lipopolysaccharide in a murine model[J]. Oncotarget, 2017, 8(44): 77407-77414.
|
38 |
Chen C, Chen Y, Sung P, et al. Effective protection against acute respiratory distress syndrome/sepsis injury by combined adipose-derived mesenchymal stem cells and preactivated disaggregated platelets[J]. Oncotarget, 2017, 8(47): 82415-82429.
|
39 |
Liu YY, Chiang CH, Hung SC, et al. Hypoxia-preconditioned mesenchymal stem cells ameliorate ischemia/reperfusion-induced lung injury[J]. PLoS One, 2017, 12(11): e0187637.
|
40 |
Hou YS, Liu LY, Chai JK, et al. Lipopolysaccharide pretreatment inhibits LPS-induced human umbilical cord mesenchymal stem cell apoptosis via upregulating the expression of cellular FLICE-inhibitory protein[J]. Mol Med Rep, 2015, 12(2): 2521-2528.
|